MedElevator
Войти в исследования Stroke · 2026
Postnatal Azithromycin Is Neuroprotective and Anti-Inflammatory in a Piglet Model of Hypoxic-Ischemic Encephalopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pang Raymand, Meehan Christopher, Maple George, Kim Yujin, D'Angelo Ilenia, Mintoft Alison, Torrealdea Francisco, Hristova Mariya, Pai Manjunath P, Barks John D E, Robertson Nicola J
Аннотация
BACKGROUND: There is an urgent need for cytoprotective therapies for hypoxic-ischemic encephalopathy in low- and middle-income countries, where therapeutic hypothermia is not beneficial. Infection and inflammation are important risk factors for hypoxic-ischemic encephalopathy in sub-Saharan Africa, and immunomodulatory therapies might improve outcomes. Azithromycin is neuroprotective in rodent hypoxic-ischemic encephalopathy models but validation in large animal models is needed. Our aim was to assess safety and efficacy of intravenous azithromycin after inflammation-amplified hypoxia-ischemia in newborn piglets.
METHODS: Twenty-five piglets underwent inflammation-amplified hypoxia-ischemia by bilateral carotid artery occlusion and reduction in FiO2 to 6% at 4 hours after the start of Escherichia coli liposaccharide infusion (2 mcg/kg bolus+1 mcg/kg per hour over 12 hours). At 1 hour after inflammation-amplified hypoxia-ischemia, piglets were randomized to receive vehicle (n=12) or azithromycin 20 mg/kg over 1 hour (n=13), repeated at 24 and 48 hours. Piglets underwent neurocritical care for 65 hours, including continuous amplitude-integrated encephalography, magnetic resonance imaging/magnetic resonance spectroscopy at 60 hours, and brain immunohistochemistry. Group differences were evaluated by Bayesian analysis with noninformative priors; the a priori threshold probability of superiority (Pr[sup]) was set at 95%.
RESULTS: Insult severity did not differ between groups. Plasma azithromycin peak concentration (Cmax) of ≈2 mg/mL and brain tissue concentrations of ≈1.5 mg/kg were achieved. Azithromycin was associated with improved amplitude-integrated encephalography background (Pr[sup]=98.6%), an overall increase in neuronal nuclear antigen (NeuN+) cells (Pr[sup]=97.8%), increase in Iba1 (ionized calcium-binding adapter molecule 1)+cells (Pr[sup]=99.6%) and increase in Iba1 ramification index (resting microglial morphology; Pr[sup]=99.6%). The treatment benefit on magnetic resonance spectroscopy lactate to N-acetyl aspartate peak area ratio was modest (Pr[sup] of 82.7% and 68.5% in the thalamic and white matter voxels, respectively).
CONCLUSIONS: Azithromycin, administered after inflammation-amplified hypoxia-ischemia was safe and associated with increased neuronal survival, microglial immunomodulation, enhanced amplitude-integrated encephalography recovery, and a modest benefit on lactate to N-acetyl aspartate peak area ratio. These safety and efficacy data of azithromycin as a monotherapy hold promise to improve outcomes for hypoxic-ischemic encephalopathy in low- and middle-income countries.
METHODS: Twenty-five piglets underwent inflammation-amplified hypoxia-ischemia by bilateral carotid artery occlusion and reduction in FiO2 to 6% at 4 hours after the start of Escherichia coli liposaccharide infusion (2 mcg/kg bolus+1 mcg/kg per hour over 12 hours). At 1 hour after inflammation-amplified hypoxia-ischemia, piglets were randomized to receive vehicle (n=12) or azithromycin 20 mg/kg over 1 hour (n=13), repeated at 24 and 48 hours. Piglets underwent neurocritical care for 65 hours, including continuous amplitude-integrated encephalography, magnetic resonance imaging/magnetic resonance spectroscopy at 60 hours, and brain immunohistochemistry. Group differences were evaluated by Bayesian analysis with noninformative priors; the a priori threshold probability of superiority (Pr[sup]) was set at 95%.
RESULTS: Insult severity did not differ between groups. Plasma azithromycin peak concentration (Cmax) of ≈2 mg/mL and brain tissue concentrations of ≈1.5 mg/kg were achieved. Azithromycin was associated with improved amplitude-integrated encephalography background (Pr[sup]=98.6%), an overall increase in neuronal nuclear antigen (NeuN+) cells (Pr[sup]=97.8%), increase in Iba1 (ionized calcium-binding adapter molecule 1)+cells (Pr[sup]=99.6%) and increase in Iba1 ramification index (resting microglial morphology; Pr[sup]=99.6%). The treatment benefit on magnetic resonance spectroscopy lactate to N-acetyl aspartate peak area ratio was modest (Pr[sup] of 82.7% and 68.5% in the thalamic and white matter voxels, respectively).
CONCLUSIONS: Azithromycin, administered after inflammation-amplified hypoxia-ischemia was safe and associated with increased neuronal survival, microglial immunomodulation, enhanced amplitude-integrated encephalography recovery, and a modest benefit on lactate to N-acetyl aspartate peak area ratio. These safety and efficacy data of azithromycin as a monotherapy hold promise to improve outcomes for hypoxic-ischemic encephalopathy in low- and middle-income countries.